A surge in dengue cases adds to the hospital burden in Covid-hit S. Asia

The latest wave of Covid-19 infections in South Asian nations has been complicated by a surge in dengue, a mosquito-transmitted virus. The rise in cases of dengue is adding to the load of hospitals that are already overwhelmed. Sri Lanka has reported over 17,000 cases this year, including 3,300 in July. Bangladesh has recorded about 4,500 cases of hospitalisation for dengue this year, nearly half of them in July. “The health system is already overburdened by Covid-19 patients,” said Dr. Himali Herath, a consultant physician at Sri Lanka’s National Dengue Control Unit. “Caring for dengue patients is labour-intensive. Therefore it will be very difficult.” The WHO estimates that there are hundreds of millions of dengue infections every year, and nearly two-thirds occur in Asia. There is no specific treatment for the virus, and severe cases can lead to death if not detected early and if patients do not receive adequate medical care.

“Due to the heavy stream of Covid-19 patients, we are turning dengue patients to other hospitals,” said Brig. Gen. Nazmul Haque, the director of the Dhaka Medical College Hospital in Bangladesh. “We are only treating the patients who are infected with both Covid and dengue.”

Dengue outbreaks also remain endemic in Nepal and Pakistan. In Kathmandu, Nepal’s capital, officials said the main hospital that treated dengue patients in previous years had been turned into a Covid hospital. The government lab where all suspected dengue cases would usually be referred to for testing has also been overwhelmed with coronavirus tests, they said.

  • Related Posts

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    New Delhi:  Indian researchers have developed an experimental “smart” cancer drug designed to remain largely inactive in healthy tissues and activate primarily inside cancer cells, potentially reducing the severe side…

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions